Logo image of ABEO

ABEONA THERAPEUTICS INC (ABEO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABEO - US00289Y2063 - Common Stock

5.43 USD
+0.32 (+6.26%)
Last: 12/22/2025, 2:22:09 PM
Fundamental Rating

2

Overall ABEO gets a fundamental rating of 2 out of 10. We evaluated ABEO against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of ABEO have multiple concerns. ABEO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ABEO has reported negative net income.
ABEO had a negative operating cash flow in the past year.
In the past 5 years ABEO always reported negative net income.
In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ABEO has a better Return On Assets (35.63%) than 98.49% of its industry peers.
ABEO has a Return On Equity of 48.09%. This is amongst the best in the industry. ABEO outperforms 98.49% of its industry peers.
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

With an excellent Profit Margin value of 20587.50%, ABEO belongs to the best of the industry, outperforming 99.81% of the companies in the same industry.
ABEO does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 20587.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABEO has been increased compared to 1 year ago.
The number of shares outstanding for ABEO has been increased compared to 5 years ago.
ABEO has a worse debt/assets ratio than last year.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

ABEO has an Altman-Z score of -1.78. This is a bad value and indicates that ABEO is not financially healthy and even has some risk of bankruptcy.
ABEO's Altman-Z score of -1.78 is in line compared to the rest of the industry. ABEO outperforms 51.13% of its industry peers.
ABEO has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.06, ABEO is doing worse than 61.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.78
ROIC/WACCN/A
WACC8.8%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 9.74 indicates that ABEO has no problem at all paying its short term obligations.
ABEO has a Current ratio of 9.74. This is in the better half of the industry: ABEO outperforms 79.81% of its industry peers.
ABEO has a Quick Ratio of 9.53. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ABEO (9.53) is better than 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.53
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

4

3. Growth

3.1 Past

ABEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.38%, which is quite impressive.
The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.52% yearly.
Based on estimates for the next years, ABEO will show a very strong growth in Revenue. The Revenue will grow by 419.83% on average per year.
EPS Next Y172.22%
EPS Next 2Y40.35%
EPS Next 3Y37.32%
EPS Next 5Y30.52%
Revenue Next Year6533.33%
Revenue Next 2Y3248.54%
Revenue Next 3Y1169.2%
Revenue Next 5Y419.83%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ABEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as ABEO's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.35%
EPS Next 3Y37.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (12/22/2025, 2:22:09 PM)

5.43

+0.32 (+6.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners66.06%
Inst Owner Change0.68%
Ins Owners5.21%
Ins Owner Change-5.08%
Market Cap294.25M
Revenue(TTM)400.00K
Net Income(TTM)82.35M
Analysts86.67
Price Target20.62 (279.74%)
Short Float %28.43%
Short Ratio7.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.03%
Min EPS beat(2)-36.14%
Max EPS beat(2)66.19%
EPS beat(4)3
Avg EPS beat(4)31.61%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)5.48%
EPS beat(12)7
Avg EPS beat(12)27.55%
EPS beat(16)9
Avg EPS beat(16)18.79%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)-4.4%
EPS NQ rev (3m)-269.47%
EPS NY rev (1m)-3.14%
EPS NY rev (3m)1383.33%
Revenue NQ rev (1m)-33.41%
Revenue NQ rev (3m)-71.2%
Revenue NY rev (1m)-75.86%
Revenue NY rev (3m)-75.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 735.63
P/FCF N/A
P/OCF N/A
P/B 1.72
P/tB 1.72
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.01
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 20587.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 476.46%
Cap/Sales 1857%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.53
Altman-Z -1.78
F-Score6
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)46.91%
Cap/Depr(5y)59.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
EPS Next Y172.22%
EPS Next 2Y40.35%
EPS Next 3Y37.32%
EPS Next 5Y30.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year6533.33%
Revenue Next 2Y3248.54%
Revenue Next 3Y1169.2%
Revenue Next 5Y419.83%
EBIT growth 1Y-36.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-95.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ABEO.


What is the valuation status for ABEO stock?

ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


Can you provide the profitability details for ABEONA THERAPEUTICS INC?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.